The mystery surrounding the U.S. scientist in the 'CRISPR babies' scandal

A picture has begun to emerge of the circumstances surrounding Michael Deem's exit from academia and his attempts since then at a second act. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        Don't miss this year's STAT Breakthrough Science Summit on March 31. Check out the agenda and speakers and secure your ticket for the hybrid event here. New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal By MEgan Molteni Michael Deem and He Jiankui. (Illustration: Alex Hogan/STAT; Photo: Rice University) There has been an enduring mystery surrounding Michael Deem, the U.S. researcher who appeared to be He Jiankui’s closest collaborator on the “CRISPR babies” experiment outside of China. STAT has learned that Deem may have been involved more extensively in the experiment than has previously been reported, and a picture has begun to emerge of the circumstances surrounding Deem’s exit from academia and his attempts since then at a second act. Read More Sponsor content by STAT 2022 STATUS List: The most definitive and consequential accounting of leaders in health, medicine, and science Meet the STATUS List — 46 individuals shaping the future of their fields. Drawn from sectors including biotechnology and diagnostics, as well as broader arenas like education and policy, each individual has taken extra steps to help others and build community in these often-divisive times. Explore the list. More great reads from STAT this week Cutting-edge gene therapies could be coming for sickle cell. Will Medicaid patients be able to access them? By Ed Silverman He was creating the building blocks for drug developers worldwide. Then Russia started to bomb Kyiv By Isabella Cueto Doctors often turn to Google Translate to talk to patients. They want a better option By Katie Palmer With infections spiking in Europe and a variant on the rise, experts warn the U.S. could face a Covid resurgence By Andrew Joseph Three years after the Senate grilled drugmakers … nothing’s changed By Nicholas Florko What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting By Adam Feuerstein Patients are flocking back to hospitals, but volumes are at the mercy of Covid surges, new documents show By Bob Herman After a dry spell for cancer immunotherapy, a new target offers a beacon of hope By Angus Chen Opinion: Commissioner Califf needs to put the F back in FDA By Bill Frist, Jerome M. Adams and Jerold Mande Saturday, March 19, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser